New warnings about Dexedrine (dextroamphetamine sulfate)

August 25, 2006 - The FDA and GlaxoSmithKline notified healthcare professionals of changes to the BOXED WARNING, WARNINGS and PRECAUTIONS sections of the prescribing information for Dexedrine (dextroamphetamine sulfate), approved for the treatment of Attention-Deficit Hyperactivity Disorder and narcolepsy. The warnings describe reports of sudden death in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.

Patients currently taking this medication should consult their physician before changing their current medication regimen.

Questions or concerns regarding this important safety information can be directed to GlaxoSmithKline at 1-888-825-5249. As always, pharmacies and members can also contact the RxAmerica customer service desk at 1-800-770-8014 if they have any questions about this new product warning.